Vertex Pharmaceuticals 8-K
PositiveEarningsGuidance raised
Cystic fibrosis, CASGEVY and JOURNAVX growth underpin a raised revenue outlook ahead of the planned Crinetics acquisition.
Filed 2026-08-03 16:09 ET
- 2.02 Results of Operations
- 9.01 Financial Statements and Exhibits
Summary
Q2 2026 results with raised FY2026 revenue guidance. Revenue grew 12.5% Y/Y, driven by continued cystic fibrosis performance and growth in other disease areas. Vertex raised its revenue outlook; current guidance excludes the pending Crinetics acquisition, for which closing is expected in Q3 2026.
Key Figures
| Metric | Q2 2026 | Q2 2025 | Y/Y |
|---|---|---|---|
| Revenue | $3.33B | $2.96B | 12.5% |
| Operating income, GAAP | $1.25B | $1.15B | 8.32% |
| Operating income, non-GAAP | $1.42B | $1.33B | 7.41% |
| Net income, GAAP | $1.1B | $1.03B | 6.48% |
| Net income, non-GAAP | $1.21B | $1.17B | 3.24% |
| Diluted EPS, GAAP | $4.31 | $3.99 | 8.02% |
| Diluted EPS, non-GAAP | $4.73 | $4.52 | 4.65% |
- Revenue growth included CF revenue of $3.21B vs $2.90B; CASGEVY revenue was $76M (+151% Y/Y), and JOURNAVX revenue was $50M vs $12M.
- Combined R&D, acquired in-process research and development, and selling, general and administrative expenses were $1.6B GAAP and $1.43B non-GAAP, up from $1.4B and $1.24B, respectively, primarily reflecting commercial investment in JOURNAVX and the renal franchise. Cash, cash equivalents and marketable securities were $13.6B at 6/30/2026 vs $12.3B at 12/31/2025; common shares outstanding were 253.3M vs 254.0M.
- Vertex agreed to acquire Crinetics for $85.00 per share in cash, an equity value of ≈$10.0B, or ≈$8.8B net of estimated cash acquired. Closing is expected in Q3 2026, subject to customary conditions.
Guidance
| Metric | Period | Guidance | Prior | Direction |
|---|---|---|---|---|
| Total revenue | FY2026 | $13.1B-$13.2B; ≈150 bp Y/Y growth benefit from foreign exchange, net of hedging | $12.95B-$13.1B | raised |
| Non-CF product revenue | FY2026 | $0.5B or greater | $0.5B or greater | reaffirmed |
| Combined GAAP R&D, acquired in-process research and development, and selling, general and administrative expenses | FY2026 | $6.3B-$6.45B | $6.3B-$6.45B | reaffirmed |
| Combined non-GAAP R&D, acquired in-process research and development, and selling, general and administrative expenses | FY2026 | $5.65B-$5.75B | $5.65B-$5.75B | reaffirmed |
| Non-GAAP effective tax rate | FY2026 | 19.5%-20.5% | 19.5%-20.5% | reaffirmed |
Expense guidance includes ≈$100M of acquired in-process research and development; the GAAP/non-GAAP difference primarily reflects $650M-$700M of stock-based compensation. Guidance includes an immaterial tariff cost impact based on currently known rates and regulations, and excludes the Crinetics acquisition; Vertex expects to update FY2026 guidance after closing.
Investor Takeaways
- Watch for the expected Q3 2026 Crinetics closing and the resulting update to FY2026 guidance.
- Povetacicept’s FDA target action date for IgA nephropathy is 11/30/2026.
The summary is written by an AI model reading the filing.
Model 005 · prompt 01d34d48e3